

Supplementary Material

Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be Used to Monitor Target Engagement

Jesse Alt¹, Sadakatali S. Gori^{1,2}, Kathryn M. Lemberg^{1,3}, Arindom Pal^{1,2}, Vijayabhaskar Veeravalli⁸, Ying Wu¹, Joanna Marie H. Aguilar¹, Ranjeet P. Dash^{1,2}, Lukáš Tenora⁹, Pavel Majer⁹, Qi Sun¹⁰, Barbara S. Slusher^{1,2,3,4,5,6,7,*} and Rana Rais^{1,2,7}

¹Johns Hopkins Drug Discovery, Department of ²Neurology, ³Oncology, ⁴Psychiatry, ⁵Neuroscience, ⁶Medicine, ⁷Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore MD 21205, USA; ⁸Drug Metabolism, Covance Laboratories Inc., Madison, WI 53704, USA; ⁹Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic v.v.i., Prague, 166 10, Czech Republic; ¹⁰Jiangxi Science and Technology Normal University Nanchang, Jiangxi 330013, PR China




Fig. (S1). ¹H NMR spectrum of FGAR.






Fig. (S2). ¹³C NMR spectrum of FGAR.

**Fig. (S3).** ³¹P NMR spectrum of FGAR.**Fig. (S4).** ESI-HRMS⁽⁻⁾ spectrum of FGAR.